APA (7th ed.) Citation

T, K., D, A., M, K., S, K., M, U., K, M., . . . R, Y. (2025). Prognostic Impact of Sarcopenia on Clinical Outcomes in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors. Cancer diagnosis & prognosis, 5(5), 597. https://doi.org/10.21873/cdp.10474

Chicago Style (17th ed.) Citation

T, Kimura, Abe D, Kitano M, Koike S, Umemoto M, Miyamoto K, Sato M, Wakasaki T, and Yasumatsu R. "Prognostic Impact of Sarcopenia on Clinical Outcomes in Patients With Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors." Cancer Diagnosis & Prognosis 5, no. 5 (2025): 597. https://doi.org/10.21873/cdp.10474.

MLA (9th ed.) Citation

T, Kimura, et al. "Prognostic Impact of Sarcopenia on Clinical Outcomes in Patients With Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors." Cancer Diagnosis & Prognosis, vol. 5, no. 5, 2025, p. 597, https://doi.org/10.21873/cdp.10474.